Overview

Beta2-adrenergic Agonism and Muscle Remodelling

Status:
Recruiting

Trial end date:
2021-05-30

Target enrollment:

Participant gender:

Summary

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

Phase:

N/A

Details

Lead Sponsor:

Morten Hostrup, PhD

Treatments:

Adrenergic Agents
Formoterol Fumarate
Terbutaline